SynOx Therapeutics raises €37M in Series A Financing
HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop … Continue reading “SynOx Therapeutics raises €37M in Series A Financing”
HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop … Continue reading “SynOx Therapeutics raises €37M in Series A Financing”
Proprietary biotech platform developing natural, non-animal leather material using patented Fine Mycelium™ … Continue reading “Novo Holdings participates in USD 45 million Series B investment in MycoWorks, creator of Reishi Fine Mycelium™ for luxury fashion and footwear brands”
Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small … Continue reading “Synendos Therapeutics Raises CHF 20 Million in Series A Financing”
Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the … Continue reading “Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising”
Biocomposites, an international medical devices company that engineers, manufactures and markets world … Continue reading “Transformational year for Biocomposites”
ValiRx (AIM: VAL) a clinical stage drug development company, announces today that … Continue reading “ValiRx enters agreement with Kalos Therapeutics”
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing … Continue reading “Arix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion”
Novo Growth, the growth equity arm of Novo Holdings, an investment and … Continue reading “Novo Holdings leads EUR 22m Series A investment in The Protein Brewery, an innovative developer of protein-rich food ingredients”
Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announced … Continue reading “Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution”
Transaction highlights Kiadis and Sanofi have reached conditional agreement on a recommended … Continue reading “Sanofi offers to acquire Kiadis for €308 million”
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate … Continue reading “Synklino Strengthens Management Team with Key Appointments”
NBE-Therapeutics, a Swiss-based company developing best-in-class cancer therapies based on its proprietary, … Continue reading “NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors”
It is with great sadness that we have to inform you that … Continue reading “Niall Kirk, Friend and Founder of Optimum Strategic Communications”
F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for … Continue reading “F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura provides regulatory and commercial update for MED3000”
STORM Therapeutics, the leading biotechnology company focused on the discovery and development … Continue reading “STORM Therapeutics selects first-in-class clinical candidate targeting METTL3”
Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase … Continue reading “Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs”
Backed by Omega Funds to develop new oral treatments for rare autoimmune diseases. … Continue reading “Chord Therapeutics launches with USD 16 million Series A financing from Omega Funds”
Novo Seeds, the early stage investment and company creation team of Novo … Continue reading “Novo Seeds co-leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A drugs”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
